TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: The Cardiac Benefit of Testosterone Replacement in Men With Low Testosterone Levels With Coronary Artery Disease After Successful Intervention of the Blockage or Narrowed Heart Artery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult male patients with coronary artery disease (CAD) (one to three vessel diseased).~* Stable cardiac status at least 3 months after percutaneous coronary intervention (PCI).~* No change in cardiac medications for 4 weeks prior to enrollment.~* Testosterone \< 300 ng/dl or free testosterone \< 5.0 ng/dl or bioavailable testosterone \< 150 ng/dl.~* Sex Hormone Binding Globulin (SHBG) \< 7nmol/liter and Free Testosterone \< 50pg/dl~* Prostate Specific Antigen (PSA) \< 2.5 ng/mL or 2.6-3.7ng/mL with a negative prostate biopsy within the last 6 months and pathology report available for investigator's review.~* Subgroup of diabetics with well to moderately controlled diabetes (defined by a HgbA1c of \< 9mg/dL.~Exclusion Criteria:~* Hematocrit greater than 50%.~* Severe hypertension (exhibit systolic blood pressure \>180mmHg and diastolic blood pressure \>110 mmHg at baseline visit or a have a history of malignant hypertension.~* Significant cardiac arrhythmia (supraventricular tachycardia \[SVT\] or ventricular tachycardia with heart rate exceeding 110 beats per minute at Visit 1).~* ECG abnormalities precluding ST segment analysis on treadmill, or inability to walk on treadmill.~* Poorly controlled, symptomatic, active medical problems (HIV, hepatitis, cancer, benign prostatic hypertrophy, alcohol or drug abuse, major depressive disorder).~* Neurological or psychiatric disorder that would compromise the patient's ability to give informed consent or adhere to the requirements of the protocol.~* History of prostate cancer~* History of hypersensitivity to transdermal testosterone gel.~* International Prostate Symptom Score (IPSS) \>19 at Visit 1.

- Gender: MALE
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Androgel treatment (Type: EXPERIMENTAL): Androgel 5 grams~Androgel treatment - subjects will be instructed to begin the study drug at 1 week post entry into the study and will continue to take the study drug for a total of 6 months. The study drug has to be applied to the skin once daily for 6 months.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo - will be instructed to begin the study drug at 1 week post entry into the study and will continue to take the study drug for a total of 6 months. The study drug has to be applied to the skin once daily for 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact of AIT on Allergic Rhinitis and Asthma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria for the AIT cohort:~* At least two index-AIT prescriptions during the first FU-year~* At least one confirmed AR diagnosis during the study period~* Continuous enrollment (no gaps in insurance time-defined by days) for 12 months before the index event (in the pre-index period)~* Continuous enrollment (no gaps in insurance time-defined by days) for at least 12 months after the index event (in the post-index period)~Inclusion Criteria for the Control Cohort:~- For the control groups, the same inclusion criteria will apply, with the exception of inclusion criterion 1, i.e. controls have not received AIT before baseline.~Exclusion Criteria:~- AIT prescription 12 months before the index event (in the pre-index period) for the AIT treatment group

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- AIT Cohort (Type: None): Allergic rhinitis patients with and without asthma treated with AIT
- Control Cohort (Type: None): Allergic rhinitis patients with and without asthma not treated with AIT

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of the Action of Drugs in the Body and Safety of N8 and Advate® in Haemophilia A Subjects

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Severe haemophilia A (FVIII level less than or equal to 1%)~* Treatment history of more than 150 exposure days with recombinant or plasma-derived FVIII replacement products~* HIV or HCV negative, or if positive the patient is on a stable antiviral regimen at the time of the enrolment in the trial~Exclusion Criteria:~* Presence of any bleeding disorder in addition to haemophilia A~* Inhibitor titre greater than or equal to 0.6 Bethesda Units (BU) at screening and past history of inhibitor~* Abnormal renal function tests~* Known hypersensitivity to Advate®

- Gender: MALE
- Minimum Age: 12 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Advate®/turoctocog alfa (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Opioid Rotation From Morphine to Methadone in Treatment of Non-malignant Pain

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18-70 years of age~* non-malignant chronic pain~* morphine use~Exclusion Criteria:~* addiction~* kidney disorders

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- switch from morphine to methadon (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Effect on Glucose Control and Safety and Tolerability of LY2148568 In Japanese Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with type 2 diabetes.~* Have a body weight of \>=50 kg.~Exclusion Criteria:~* Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.~* Have participated in this study previously, or any other study using exenatide or other GLP-1 analogs.~* Are treated with any exogenous insulin within 3 months of screening.~* Are continuously treated with any of the following excluded medications within 3 months of screening (more than 7 days per 1 month): \*drugs that directly affect gastrointestinal motility, including Nauzelin® (domperidone), Primperan®/Terperan® (metoclopramide), Ganaton® (itopride), Acenalin® (cisapride), Gasmotin® (mosapride), or Cerekinon® (trimebutine).~* Have characteristics contraindicating for concomitant medication, according to product-specific label.~* Have severe allergy or hypersensitivity to any drug.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Exenatide 5 mcg/exenatide 10 mcg (Type: EXPERIMENTAL): None
- Exenatide 5 mcg/exenatide 5 mcg (Type: EXPERIMENTAL): None
- Exenatide 2.5 mcg/exenatide 2.5 mcg (Type: EXPERIMENTAL): None
- Placebo/placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Extended-Release Naltrexone for Opioid Relapse Prevention Following Release From Jail

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults incarcerated in NYC jails with known release date~* DSM-IV criteria for current opioid dependence~* No current agonist (methadone, buprenorphine) treatment~* Currently opioid free by history ('detoxed') and with a negative urine for all opioids~* General good health as determined by complete medical interview and physical examination~* Age 18-60 years.~Exclusion Criteria:~* History of liver failure, cirrhosis, or recent liver function test levels greater than three times normal~* Pregnancy, lactation, or planning conception~* Active medical illness that might make participation hazardous~* Untreated psychiatric disorder~* History of allergic reaction to naltrexone, PLG (polylactide co-glycolide), carboxymethylcellulose, or any other components of the diluent.~* Current chronic pain condition treated with opioids.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Extended-release naltrexone (XR-NTX) (Type: ACTIVE_COMPARATOR): A single 380mg IM depot injection of XR-NTX in the week prior to release from jail. A second 380mg IM injection is offered to persons in the XR-NTX arm post-release and 4 weeks after the initial injection.
- Motivational Enhancement Counseling Only (Type: PLACEBO_COMPARATOR): The randomized control arm receives no medication treatment and is offered brief, two-session Motivational Enhancement counseling prior to release from jail.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects were 16 to 70 years, both inclusive. Subjects under 18 years of age were only included where legally permitted and ethically accepted~* Subjects with well-characterized focal epilepsy or epileptic syndrome according to the International League Against Epilepsy (ILAE) classification~* Subjects had a history of partial onset seizures (POS) whether or not secondarily generalized (Type I seizures according to the ILAE classification)~* Subjects had at least 2 POS whether or not secondarily generalized per month during the 3 months preceding Visit 1 (V1)~* Subjects had at least 8 POS whether or not secondarily generalized during the 8-Week Baseline Period~* Subjects were uncontrolled while treated by 1 to 2 permitted concomitant antiepileptic drug(s) (AEDs). Vagal nerve stimulation (VNS) was allowed and was not counted as a concomitant AED~Exclusion Criteria:~* History or presence of seizures occurring only in clusters (too frequently or indistinctly separated to be reliably counted) before Visit 3~* History or presence of status epilepticus during the year preceding Visit 1 or during Baseline

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Matching Placebo tablets administered twice a day. Daily oral dose of two equal intakes, morning and evening, of Placebo in a double-blinded way for the 12-week Treatment Period.
- Brivaracetam 5 mg/day (Type: EXPERIMENTAL): Brivaracetam 5 mg/day, 2.5 mg administered twice a day. Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 5 mg /day in a double-blinded way for the 12-week Treatment Period.
- BRV 20mg/day (Type: EXPERIMENTAL): Brivaracetam 20 mg/day, 10 mg administered twice a day. Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 20 mg /day in a double-blinded way for the 12-week Treatment Period.
- BRV 50mg/day (Type: EXPERIMENTAL): Brivaracetam 50 mg/day, 25 mg administered twice a day. Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 50 mg /day, in a double-blinded way for the 12-week Treatment Period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effectiveness of a Decision-Support Tool for Adult Consumers With Mental Health Needs and Their Care Managers

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women over the age of 18 who are receiving mental health services.~Exclusion Criteria:~Temporary Exclusion:~* Disruptive, aggressive, or severely disorganized behaviors;~* Visibly intoxicated or under the influence of illicit drugs.~General Exclusion:~* Moderate to severe cognitive impairment;~* Developmental disability that precludes comprehension;~* Language issues: Intervention is only offered in English and Chinese;~* Patient services structured for provision of mPOWR implementation (e.g., not in and out of inpatient or crisis stabilization services).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- mPOWR System (Type: EXPERIMENTAL): Moving Patient Outcomes toward Wellness and Recovery (mPOWR) consists of an assessment questionnaire and decision support tools which map onto 6 life domains which are measured by the questionnaire.
- Control (Type: NO_INTERVENTION): Treatment as usual

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Provider Awareness and Cultural Dexterity Toolkit for Surgeons Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
\*Eligibility Criteria for Residents:~Inclusion Criteria:~- All residents in the general surgery program at Johns Hopkins University, Brigham and Women's Hospital, Brown University, Eastern Virginia Medical School, Massachusetts General Hospital, Beth Israel Deaconess Medical Center, Howard University, and Washington University in St. Louis.~Exclusion Criteria:~- Non-surgical residents at Johns Hopkins University, Brigham and Women's Hospital, Brown University, Eastern Virginia Medical School, Massachusetts General Hospital, Beth Israel Deaconess Medical Center, Howard University, and Washington University in St. Louis.~\*Eligibility Criteria for Patients:~Inclusion Criteria:~* Admitted to surgical service under the care of a participating resident;~* Able to recognize resident as the main care provider from a photo;~* Able to consent as determined by a cognitive screen for capacity to give informed consent~* Fluent in English or Spanish.~Exclusion Criteria:~* Admitted to Intensive Care;~* Mentally impaired and/or not oriented to person/time/ place.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Early Intervention Group (Type: EXPERIMENTAL): The investigators will assess the residents' knowledge, attitudes, and skills prior to and after the PACTS curriculum administration at half the sites (Early Intervention Group). Evaluation results in the Early Intervention Group will be compared to the Delayed Intervention (Active Comparator) group at time Period 2.
- Delayed Intervention Group (Type: ACTIVE_COMPARATOR): The investigators will conduct baseline testing prior to the standard residency curriculum. These results will be compared to the Early Intervention Group (Experimental Group) at time period 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Autistic Disorder

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The patient meets Autistic disorder diagnostic criteria defined in DSM-IV-TR.~* The patient has completed the 031-11-002 study (the patient has visited the hospital during week8)~* Inpatient or outpatient status~Exclusion Criteria:~* The patient is currently diagnosed with another disorder on the autism spectrum in DSM-IV-TR, including Asperger's, Rett's Disorder, PDD-NOS, Childhood Disintegrative Disorder, or Fragile-X Syndrome.~* Patients who fall under a contraindication listed in the ABILIFY package insert~* Others

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Aripiprazole (Type: EXPERIMENTAL): administered orally once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Albumin Dialysis to Treat Patients With Hepatic Encephalopathy Using The Molecular Adsorbent Recirculating System (MARS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed written informed consent by patient or patient's legally appointed representative~2. Be at least 18 years of age; male or female~3. Have chronic end stage liver disease with worsening Hepatic Encephalopathy (Grades 3,4).~Exclusion Criteria:~1. Clinically significant bleeding from gastrointestinal or other site within the last 24 hours and requires 2 or more units of blood to maintain a stable hemoglobin level~2. Hemodynamically unstable or on vasopressor agents for blood pressure support (except for renal-dosed dopamine)~3. On acute or chronic hemodialysis or continuous renal replacement therapy (CRRT)~4. Pregnancy~5. Inability to obtain informed consent~6. Uncontrolled sepsis as defined by hemodynamic instability~7. Post-liver transplant~8. Fulminant hepatic failure~9. Irreversible brain damage as indicated by the neurologic examination and CT imaging~10. Endocarditis~11. Pulmonary edema~12. Massive aspiration pneumonia secondary to Hepatic Encephalopathy~13. Active alcohol consumption as determined by a positive blood ethanol level on enrollment/admission~14. Acute main portal vein thrombosis in patients with Hepatocellular Carcinoma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1: Standard Medical Therapy + MARS (Type: EXPERIMENTAL): Patients who were randomized to Group 1 received daily MARS treatments in addition to Standard Medical Therapy for 5 consecutive days.
- Group 2: Standard Medical Therapy Only (Type: ACTIVE_COMPARATOR): Patients who were randomized to Group 2 received standard medical treatment only.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intestinal Permeability in Preterm Infants

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* \<5 days~* Gestational age 24-32 weeks~Exclusion criteria:~* Nonviable or planned withdrawal of care~* Significant GI dysfunction (e.g. heme-positive stools, abdominal distension (girth \>2 cm baseline), or bilious emesis/aspirates.~* Triplet or higher order multiple~* Severe asphyxia~* Lethal chromosome abnormalities~* Cyanotic congenital heart disease~* Intestinal atresia or perforation~* Abdominal wall defects~* Known galactosemia or other galactose intolerance

- Gender: ALL
- Minimum Age: None
- Maximum Age: 4 Days
- Healthy Volunteers: f

Study Arms:
- Lactulose - rhamnose solution (Type: OTHER): Preterm Infants age 24-32 weeks gestation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunotherapy of Melanoma Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with microscopically detectable lymph node metastases~* Positive detection of the Melan-A gene +/- MAGE-10 in positive sentinel node or primary tumor tissue by polymerase chain reaction (PCR) analysis of mRNA and/or by immunohistochemistry using monoclonal antibodies~* Human leukocyte antigen-A2 (HLA-A2) positive~Exclusion Criteria:~* Previous splenectomy or radiotherapy to the spleen~* Treatment with systemic antihistamines, corticosteroids, or non-steroidal anti-inflammatory drugs (except occasional or low dose non-steroidal anti-inflammatory drugs such as 100 mg aspirin/day) within 4 weeks of entry into the study~* Heart disease (New York Heart Association \[NYHA\] Class III or IV)~* Serious illness, e.g. active infections requiring antibiotics, bleeding disorders or other diseases considered by the investigator to have potential for interfering with obtaining accurate results from this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete